IPCA Labs: On the path to recovery

At Rs. 692, the stock now trades at a little over 15 times and about 13 times its 2014-15 and 2015-16 expected earnings respectively. This implies a discount of over 15 per cent to its historical average. Despite modest growth in the current fiscal, IPCA’s long-term growth drivers are intact — healthy growth in the domestic and emerging markets, scale-up in the institutional anti-malarial business and pick-up in US sales, post-resolution. Investors with a two-to-three year horizon can use the weakness in prices to buy into the stock.

http://www.thehindubusinessline.com/money-wise/stock-insight/on-the-path-to-recovery/article6299294.ece?homepage=true